NCT07194889Not yet recruiting
Validation of Heart Failure Risk Scores MAGGIC, GWTG-HF, and SHFM in Egyptian Patients
External Validation and Recalibration of Heart Failure Risk Models (MAGGIC, GWTG-HF, and SHFM) in Egyptian Patients
Source: ClinicalTrials.gov · Last updated 1 Oct 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Heart failure (HF) affects over 64 million people worldwide and carries high morbidity, frequent hospitalizations, and major economic burden. Accurate risk stratification is essential to guide therapy, follow-up, and advanced care decisions. Several prognostic models have been developed: MAGGIC: based on \>39,000 patients, predicts mortality from simple clinical variables. GWTG-HF: derived from \>30,000 patients, predicts in-hospital mortality using admission data. SHFM: estimates 1-3 year survival, incorporating clinical, lab, and treatment factors. These models, developed mainly in Western cohorts, may not perform well in Arab populations, where HF patients are younger, with more ischemic disease, diabetes, CKD, and limited access to advanced therapies. Such differences risk score miscalibration. External validation and recalibration are needed to assess predictive accuracy and adjust models for local populations. A head-to-head comparison of MAGGIC, GWTG-HF, and SHFM has never been done in Egypt; such a study would identify the most reliable model for predicting 1-year mortality and 30-day readmission in Egyptian HF patients.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 140 (estimated)
- First submitted
- 19 Sept 2025
- Start date
- 1 Oct 2025
- Primary completion date
- Oct 2026
- Lead sponsor
- Assiut University
- Diseases
- Heart failure
- NCT number
- NCT07194889
What you commit to
- Study type: Observational
- Planned participants: 140
- From 1 Oct 2025 to the primary completion date, Oct 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Criteria the registry did not label
- Inclusion criteria:
- Age ≥18 years.
- Clinical HF diagnosis (per ESC/ACC/AHA criteria).
- Available baseline data to compute ≥1 of the three scores within 24h of index assessment (admission or clinic baseline).
- For longitudinal endpoints: reachable for follow-up.
- Exclusion criteria:
- Cardiogenic shock requiring immediate MCS at presentation (analyzed separately).
- Isolated right HF from primary pulmonary disease without LV involvement (for main analysis
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.